Ibuprofen and indomethacin for the closure of the patent ductus arteriosus

Detalhes bibliográficos
Autor(a) principal: Pacifici,Gian Maria
Data de Publicação: 2016
Tipo de documento: Artigo
Idioma: eng
Título da fonte: MedicalExpress (São Paulo. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292016000300001
Resumo: The ductus arteriosus connects the pulmonary artery with the aorta and allows right ventricular blood to bypass the unexpanded lungs. In mature infants, the ductus arteriosus closes after birth. Patent ductus arteriosus occurs in 70% of preterm infants with a birth weight < 1,000 grams. Failure of the ductus arteriosus to close has been associated with intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, periventricular leukomalacia, renal failure, and persistent pulmonary hypertension. The drugs used to treat the patent ductus arteriosus are ibuprofen and indomethacin which are potent non-selective inhibitors of cyclo-oxygenase (COX) and therefore inhibit prostaglandin E2 synthesis. Prostaglandin E2 relaxes smooth muscle and tends to inhibit the closure of the patent ductus arteriosus. Intravenous ibuprofen and indomethacin inhibit prostaglandin E2 synthesis and thereby close the patent ductus arteriosus with similar efficacy. Indomethacin reduces the blood flow velocity in kidneys, intestine and brain. Ibuprofen has less effect on blood flow velocity in these organs. There is a significant increase in serum creatinine after indomethacin administration but not after ibuprofen and infants treated with ibuprofen have higher creatinine clearance. Oliguria (urine output < 1 ml/kg/h) occurs more frequently with indomethacin than with ibuprofen. Indomethacin requires furosemide for urine output more often than ibuprofen. Ibuprofen reduces the risk of necrotizing enterocolitis and transient renal insufficiency and it is the drug of choice for closing the patent ductus arteriosus. Ibuprofen and indomethacin may be administered orally. In conclusion, intravenous ibuprofen and indomethacin close the patent ductus arteriosus at the same rate, but indomethacin is more toxic than ibuprofen.
id METC-1_832b604877707d7feb1d3385793cd127
oai_identifier_str oai:scielo:S2358-04292016000300001
network_acronym_str METC-1
network_name_str MedicalExpress (São Paulo. Online)
repository_id_str
spelling Ibuprofen and indomethacin for the closure of the patent ductus arteriosusIbuprofenIndomethacinNeonatePatent-ductus-arteriosusThe ductus arteriosus connects the pulmonary artery with the aorta and allows right ventricular blood to bypass the unexpanded lungs. In mature infants, the ductus arteriosus closes after birth. Patent ductus arteriosus occurs in 70% of preterm infants with a birth weight < 1,000 grams. Failure of the ductus arteriosus to close has been associated with intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, periventricular leukomalacia, renal failure, and persistent pulmonary hypertension. The drugs used to treat the patent ductus arteriosus are ibuprofen and indomethacin which are potent non-selective inhibitors of cyclo-oxygenase (COX) and therefore inhibit prostaglandin E2 synthesis. Prostaglandin E2 relaxes smooth muscle and tends to inhibit the closure of the patent ductus arteriosus. Intravenous ibuprofen and indomethacin inhibit prostaglandin E2 synthesis and thereby close the patent ductus arteriosus with similar efficacy. Indomethacin reduces the blood flow velocity in kidneys, intestine and brain. Ibuprofen has less effect on blood flow velocity in these organs. There is a significant increase in serum creatinine after indomethacin administration but not after ibuprofen and infants treated with ibuprofen have higher creatinine clearance. Oliguria (urine output < 1 ml/kg/h) occurs more frequently with indomethacin than with ibuprofen. Indomethacin requires furosemide for urine output more often than ibuprofen. Ibuprofen reduces the risk of necrotizing enterocolitis and transient renal insufficiency and it is the drug of choice for closing the patent ductus arteriosus. Ibuprofen and indomethacin may be administered orally. In conclusion, intravenous ibuprofen and indomethacin close the patent ductus arteriosus at the same rate, but indomethacin is more toxic than ibuprofen.Mavera Edições Técnicas e Científicas Ltda2016-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292016000300001MedicalExpress v.3 n.3 2016reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2016.03.01info:eu-repo/semantics/openAccessPacifici,Gian Mariaeng2016-06-14T00:00:00Zoai:scielo:S2358-04292016000300001Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-06-14T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse
dc.title.none.fl_str_mv Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
title Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
spellingShingle Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
Pacifici,Gian Maria
Ibuprofen
Indomethacin
Neonate
Patent-ductus-arteriosus
title_short Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
title_full Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
title_fullStr Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
title_full_unstemmed Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
title_sort Ibuprofen and indomethacin for the closure of the patent ductus arteriosus
author Pacifici,Gian Maria
author_facet Pacifici,Gian Maria
author_role author
dc.contributor.author.fl_str_mv Pacifici,Gian Maria
dc.subject.por.fl_str_mv Ibuprofen
Indomethacin
Neonate
Patent-ductus-arteriosus
topic Ibuprofen
Indomethacin
Neonate
Patent-ductus-arteriosus
description The ductus arteriosus connects the pulmonary artery with the aorta and allows right ventricular blood to bypass the unexpanded lungs. In mature infants, the ductus arteriosus closes after birth. Patent ductus arteriosus occurs in 70% of preterm infants with a birth weight < 1,000 grams. Failure of the ductus arteriosus to close has been associated with intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia, periventricular leukomalacia, renal failure, and persistent pulmonary hypertension. The drugs used to treat the patent ductus arteriosus are ibuprofen and indomethacin which are potent non-selective inhibitors of cyclo-oxygenase (COX) and therefore inhibit prostaglandin E2 synthesis. Prostaglandin E2 relaxes smooth muscle and tends to inhibit the closure of the patent ductus arteriosus. Intravenous ibuprofen and indomethacin inhibit prostaglandin E2 synthesis and thereby close the patent ductus arteriosus with similar efficacy. Indomethacin reduces the blood flow velocity in kidneys, intestine and brain. Ibuprofen has less effect on blood flow velocity in these organs. There is a significant increase in serum creatinine after indomethacin administration but not after ibuprofen and infants treated with ibuprofen have higher creatinine clearance. Oliguria (urine output < 1 ml/kg/h) occurs more frequently with indomethacin than with ibuprofen. Indomethacin requires furosemide for urine output more often than ibuprofen. Ibuprofen reduces the risk of necrotizing enterocolitis and transient renal insufficiency and it is the drug of choice for closing the patent ductus arteriosus. Ibuprofen and indomethacin may be administered orally. In conclusion, intravenous ibuprofen and indomethacin close the patent ductus arteriosus at the same rate, but indomethacin is more toxic than ibuprofen.
publishDate 2016
dc.date.none.fl_str_mv 2016-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292016000300001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292016000300001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/MedicalExpress.2016.03.01
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
dc.source.none.fl_str_mv MedicalExpress v.3 n.3 2016
reponame:MedicalExpress (São Paulo. Online)
instname:Mavera Edições Científicas e Técnicas Ltda-ME
instacron:METC
instname_str Mavera Edições Científicas e Técnicas Ltda-ME
instacron_str METC
institution METC
reponame_str MedicalExpress (São Paulo. Online)
collection MedicalExpress (São Paulo. Online)
repository.name.fl_str_mv MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME
repository.mail.fl_str_mv ||medicalexpress@me.net.br
_version_ 1754734597039456256